| Transplant patients (n = 22) | Healthy volunteers (n = 10) | p value |
---|---|---|---|
Male | 17 (77%) | 7 (70%) | 0.660 |
Age (years) | 49 ± 10 | 49 ± 8 | 0.961 |
Non-white | 2 (9%) | 1 (10%) | 0.676 |
BSA (m2) | 1.86 ± 0.20 | 1.94 ± 0.19 | 0.290 |
BMI (kg/m2) | 24.7 ± 3.6 | 25.7 ± 4.1 | 0.484 |
eGFR (mL/min/m2) | 61 ± 24 | 89 ± 13 | <0.001 |
HR (bpm) | 89 ± 15 | 60 ± 6 | <0.001 |
Systolic BP (mmHg) | 135 ± 17 | 111 ± 8 | <0.001 |
Indication for transplant | Â | Â | Â |
 DCM | 12 (55%) | - |  |
 IHD | 6 (27%) | - |  |
 ARVC | 2 (9%) | - |  |
 HCM | 1 (5%) | - |  |
 Re-transplant | 1 (5%) | - |  |
Pregnancy prior to transplantation | 3 (14%) | - | Â |
VAD prior to transplantation | 1 (5%) | - | Â |
Donor age (years) | 42 ± 7 | - |  |
Donor male | 17 (77%) | - | Â |
Donor: recipient gender match | 18 (82%) | - | Â |
Donor cause of death | Â | Â | Â |
 ICH | 13 (59%) | - |  |
 Head trauma | 5 (23%) | - |  |
 Other | 4 (18%) | - |  |
CMV donor pos., recipient neg. | 5 (23%) | - | Â |
Ischaemic time (min) | 184 ± 52 | - |  |
Induction immunosuppression | Â | Â | Â |
 rATG | 21 (95%) | - |  |
 Basiliximab | 1 (5%) | - |  |
Initial immunosuppression regime | Â | Â | Â |
 Cyclosporine/prednisolone/MMF | 21 (95%) | - |  |
 Tacrolimus/prednisolone/MMF | 1 (5%) | - |  |
ICU stay (days) | 17 ± 19 | - |  |
Hospital stay (days) | 36 ± 23 | - |  |